Initial studies on patients with Sickle Cell Disease were carried out which included gene editing as a form of treatment.
Sickle Cell Disease (SCD) is a painful blood disorders affecting millions worldwide.
Doctors are optimistic that a one-time gene-editing treatment involving permanent alteration of DNA in blood cells with the help of CRISPR, can not only treat, but also possibly cure SCD and beta-thalassemia.
Partial results from the research were presented on Saturday at a conference of the American Society of Hematology, and some were even published by the New England Journal of Medicine.
Researchers undertook 10 patients for the initial study. These patients were away from their regular treatment for several months.
All of them were no longer in need of regular blood transfusions and are free from pain crises that affected their life in the past.